227. Osler disease Clinical trials / Disease details


Clinical trials : 56 Drugs : 72 - (DrugBank : 21) / Drug target genes : 23 - Drug target pathways : 136

  
1 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2018-004179-11-DE
(EUCTR)
12/08/202012/03/2020The effectiveness of Octreotide in hereditary hemorrhagic telangiectasia(a.k.a. Rendu-Osler-Weber disease) patients who suffer fromgastrointestinal bleeding.Effectiveness of Somatostatin Analogues in Patients with hereditaryhemorrhagic telangiectasia and symptomatic gastrointestinal bleeding,the SAIPAN-trial: a multicenter, randomized, open-label, parallel-group,superiority trial. - SAIPAN-trial Hereditary hemorrhagic telangiectasia (HHT), also known as Osler–Weber–Rendu disease (in specific patients with gastrointestinalbleedings);Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]Other descriptive name: OCTREOTIDE ACETATERadboudumcNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
38Phase 3France;Netherlands;Germany;United Kingdom;Italy